TY - JOUR
T1 - Antiretroviral drug resistance testing in adults infected with human immunodefidency virus type 1
T2 - 2003 Recommendations of an International Aids Society-USA panel
AU - Hirsch, Martin S.
AU - Brun-Vézinet, Françoise
AU - Clotet, Bonaventura
AU - Conway, Brian
AU - Kuritzkes, Daniel R.
AU - D'Aquila, Richard T.
AU - Demeter, Lisa M.
AU - Hammer, Scott M.
AU - Johnson, Victoria A.
AU - Loveday, Clive
AU - Mellors, John W.
AU - Jacobsen, Donna M.
AU - Richman, Douglas D.
N1 - Funding Information:
Financial support: The International AIDS Society–USA is funded through a reserve fund independent of commercial company support.
PY - 2003/7/1
Y1 - 2003/7/1
N2 - New information about the benefits and limitations of testing for resistance to human immunodeficiency virus (HIV) type 1 (HIV-1) drugs has emerged. The International AIDS Society-USA convened a panel of physicians and scientists with expertise in antiretroviral drug management, HIV-1 drug resistance, and patient care to provide updated recommendations for HIV-1 resistance testing. Published data and presentations at scientific conferences, as well as strength of the evidence, were considered. Properly used resistance testing can improve virological outcome among HIV-infected individuals. Resistance testing is recommended in cases of acute or recent HIV infection, for certain patients who have been infected as long as 2 years or more prior to initiating therapy, in cases of antiretroviral failure, and during pregnancy. Limitations of resistance testing remain, and more study is needed to refine optimal use and interpretation.
AB - New information about the benefits and limitations of testing for resistance to human immunodeficiency virus (HIV) type 1 (HIV-1) drugs has emerged. The International AIDS Society-USA convened a panel of physicians and scientists with expertise in antiretroviral drug management, HIV-1 drug resistance, and patient care to provide updated recommendations for HIV-1 resistance testing. Published data and presentations at scientific conferences, as well as strength of the evidence, were considered. Properly used resistance testing can improve virological outcome among HIV-infected individuals. Resistance testing is recommended in cases of acute or recent HIV infection, for certain patients who have been infected as long as 2 years or more prior to initiating therapy, in cases of antiretroviral failure, and during pregnancy. Limitations of resistance testing remain, and more study is needed to refine optimal use and interpretation.
UR - http://www.scopus.com/inward/record.url?scp=0038234808&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0038234808&partnerID=8YFLogxK
U2 - 10.1086/375597
DO - 10.1086/375597
M3 - Article
C2 - 12830416
AN - SCOPUS:0038234808
SN - 1058-4838
VL - 37
SP - 113
EP - 128
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 1
ER -
